A LIFE-EXTENDING ovarian cancer drug has been rejected for NHS use in Scotland after the medicines watchdog ruled it was not value for money.
The Scottish Medicines Consortium said it could not approve bevacizumab (Avastin) for routine use on the health service because the main case submitted by its manufacturer, Roche, was based on a 7.5mg unlicensed dose which was trialled in Scotland as part of a European study.
We moderate all comments on HeraldScotland on either a pre-moderated or post-moderated basis. If you're a relatively new user then your comments will be reviewed before publication and if we know you well then your comments will be subject to moderation only if other users or the moderators believe you've broken the rules, which are available here.
Moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours. Please be patient if your posts are not approved instantly.
